https://scholars.lib.ntu.edu.tw/handle/123456789/544421
標題: | Anthraquinone derivatives induce G2/M cell cycle arrest and apoptosis in NTUB1 cells | 作者: | Tu H.-Y. Huang A.-M. Teng C.-H. Hour T.-C. Yang S.-C. YEONG-SHIAU PU Lin C.-N. |
關鍵字: | Anthraquinone; Anticancer; Bax; CyclinB1; p21; p53; Reactive oxygen species; Synthesis | 公開日期: | 2011 | 卷: | 19 | 期: | 18 | 起(迄)頁: | 5670-5678 | 來源出版物: | Bioorganic and Medicinal Chemistry | 摘要: | Thirteen anthraquinone derivatives 5-17 including two 3-(3- alkylaminopropoxy)-9,10-anthraquinone (NHA) derivatives 5 and 6, and 11 1-hydroxy-3-(3-alkylaminopropoxy)-9,10-anthraquinone (MHA) derivatives 7-17 were synthesized, evaluated for cytotoxicities against two cancer cell lines, and assayed the generation of reactive oxygen species (ROS) in NTUB1 cells (a human bladder carcinoma cell line). Compound 9 bearing a pyrrolidinyl group induced the stronger cytotoxic effect than those of other synthesized NHA and MHA derivatives. Exposure of NTUB1 cells to 9, 13, and 17 for 24 h significantly increased the production of ROS, respectively. Flow cytometric analysis exhibited that the exposure of NTUB1 cells to the selective 9 led to the G2/M phase arrest accompanied by an increase of apoptotic cell death after the incubation for 24 h. Compound 9 induced up-regulation of cyclinB1 and p21 expressions. Biological results suggested that the induction of G2/M arrest, apoptosis, and cell death by 9 may associate with increased expression of p21 and cyclin B1, elevation of Bax and p53 levels, and generation of ROS in the cell. In conclusion, these series of compounds may be used as anticancer agents. ? 2011 Elsevier Ltd. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-80052571005&doi=10.1016%2fj.bmc.2011.07.021&partnerID=40&md5=965b0bbc89bf58d67dce0a3f477e2c12 https://scholars.lib.ntu.edu.tw/handle/123456789/544421 |
ISSN: | 0968-0896 | DOI: | 10.1016/j.bmc.2011.07.021 | SDG/關鍵字: | 1 hydroxy 3 [3 (2 hydroxypropylamino)propxy] 9,10 anthraquinone; 1 hydroxy 3 [3 (4 methylpiperazin 1 yl)propxy] 9,10 anthraquinone; 1 hydroxy 3 [3 (cyclohexylamino)propxy] 9,10 anthraquinone; 1 hydroxy 3 [3 (ethylamino)propoxyl] 9,10 anthraquinone; 1 hydroxy 3 [3 (morpholin 4 yl)propxy] 9,10 anthraquinone; 1 hydroxy 3 [3 (piperidin 1 yl)propxy] 9,10 anthraquinone; 1 hydroxy 3 [3 (propylamino)propoxyl] 9,10 anthraquinone; 1 hydroxy 3 [3 (pyrrolidin 1 yl)propoxyl] 9,10 anthraquinone; 1 hydroxy 3 [3 [(2 hydroxyethyl)methylamino]propxy] 9,10 anthraquinone; 1 hydroxy 3 [3 [4 (2 hydroxyethyl)piperazin 1 yl]propxy] 9,10 anthraquinone; 3 [3 (dimethylamino)propoxyl] 9,10 anthraquinone; 3 [3 (ethylamino)propoxyl] 9,10 anthraquinone; 4 [3 (4 hydroxy 9,10 dioxo 9,10 dihydro anthracen 2 yloxy)propyl]piperazine 1 carboxylic acid ethyl ester; anthraquinone derivative; cyclin B1; cyclin dependent kinase inhibitor 1; cyclin dependent kinase inhibitor 1B; protein Bax; protein Noxa; protein p53; PUMA protein; unclassified drug; apoptosis; article; cancer cell culture; cell cycle arrest; cell cycle G2 phase; cell cycle M phase; cell cycle progression; cell cycle S phase; cell death; down regulation; drug cytotoxicity; drug screening; drug structure; drug synthesis; drug toxicity; fluorescence activated cell sorting; human; immunofluorescence; quantitative analysis; upregulation; Anthraquinones; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; G2 Phase; Humans; Molecular Structure; Stereoisomerism; Structure-Activity Relationship |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。